Precision medicine in type 2 diabetes: targeting SGLT2 inhibitor treatment for kidney protection.

ABSTRACT:

Aims/hypothesis

Current guidelines recommend use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) for kidney protection in people with type 2 diabetes and early-stage chronic kidney disease (CKD) based on a urinary albumin/creatinine ratio (uACR) of ≥3 mg/mmol. However, individuals with a normal uACR or low-level albuminuria were not represented in kidney outcome trials, leaving uncertainty about absolute treatment benefit in this group. To address this gap and support treatment decisions in clinical practice, we developed and validated a model to predict individual-level kidney protection benefit through the use of SGLT2 inhibitors.

Methods

This observational cohort study used electronic health record data from UK primary care (Clinical Practice Research Data

SUBMITTER: Jansz TT 

PROVIDER: S-EPMC12779664 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature